Germany Cannabis Legalisation: The Business Guide 2026

Background: The Cannabis Act and What It Changed

On 1 April 2024, Germany's Gesetz zum Umgang mit Konsumcannabis — the Cannabis Act, universally abbreviated as CanG — entered into force. The legislation represented the most consequential reform to German narcotics law since the Betäubungsmittelgesetz (BtMG) was enacted in 1971. For international operators monitoring European cannabis regulation, it marked a structural shift that altered the continent's regulatory centre of gravity.

The CanG accomplished several things simultaneously. It removed cannabis from Schedule I of the BtMG — the list of substances with no accepted medical use and high potential for abuse — and reclassified medical cannabis products under the Arzneimittelgesetz (AMG), the Medicines Act. It legalised the personal possession of up to 25g of cannabis for adults, permitted home cultivation of up to three plants, and created the legal framework for non-profit Cannabis Social Clubs. It also set the stage — but did not complete — a commercial supply architecture, which is being developed under the separate Pillar 2 framework.

The broader context matters for business strategy. Germany is the EU's largest economy, home to 84 million people, and had already established itself as Europe's dominant medical cannabis market before legalisation. The CanG did not create the German market — it transformed the regulatory conditions under which that market operates, and it opened a pathway to a vastly larger adult-use consumer segment that no other major EU economy has yet unlocked.

German Cannabis Reform: Key Timeline

• 2017
  Medical cannabis legalised Germany becomes the first major EU economy to permit medical cannabis prescriptions through regular pharmacies. GKV reimbursement pathway established but contested.
• 2021
  Coalition agreement commits to legalisation The SPD–Greens–FDP "traffic light" coalition publishes its Koalitionsvertrag, explicitly committing to legalise cannabis for adult use through a "controlled supply to adults in licensed shops".
• Apr 2024
  Cannabis Act (CanG) enters into force — Pillar 1 Possession of up to 25g legalised, home cultivation permitted (up to three plants), Social Club framework established. Medical cannabis moved from BtMG to AMG.
• Jul 2024
  Social Club licensing opens Local authorities across Germany begin accepting Anbauvereinigung licence applications. BfArM oversight framework published. Initial licences granted in Berlin, Hamburg and Cologne.
• 2025
  Medical market accelerates; Pillar 2 legislation progresses Prescription volumes triple year-on-year. Over 100,000 patients receiving cannabis under GKV reimbursement. Federal government publishes draft Pillar 2 model framework for regional commercial pilots.
• 2026+
  Pillar 2 pilot programmes anticipated Berlin, Hamburg and Munich expected as early adopter regions. Operators begin securing supply chain positions. Commercial retail infrastructure in development.

The Two-Pillar Architecture

The CanG's architecture is intentionally phased. Pillar 1 — the personal cultivation and Social Club framework — is fully operational. Pillar 2 — the regional commercial supply and retail pilot programme — is pending and represents the larger commercial opportunity.

This two-pillar approach reflects both political pragmatism and legal caution. Germany's obligations under the 1961 Single Convention on Narcotic Drugs create genuine international law constraints on establishing a fully commercial cannabis market. The Bundesgesundheitsministerium (Federal Ministry of Health) has acknowledged this tension and structured Pillar 2 specifically as a time-limited scientific pilot — a model that draws on Switzerland's experience with its adult-use cannabis pilot programmes.

The distinction matters for operators. Pillar 1 creates a regulated supply ecosystem — Social Clubs producing cannabis — but not a commercial retail channel. Pillar 2, once operational, will create licensed retail outlets, enabling commercial cultivation, processing, distribution and sale in participating regions. The scale of opportunity between the two pillars is not comparable: Pillar 2 is where the multi-hundred-million-euro revenue potential sits.

Cannabis Social Clubs (Anbauvereinigungen)

The Social Club model introduced by the CanG is unlike any comparable framework in Europe. Clubs are licensed non-profit associations — legally structured as Vereine under German civil law — that cultivate cannabis collectively for their members. They do not sell cannabis; they distribute it to members who have collectively funded its production.

Licence Requirements and Restrictions

The core parameters are tightly defined by the CanG and are not negotiable at local authority level:

Application Process and BfArM Oversight

Licence applications are submitted to the relevant Kreisbehörde (local authority) rather than to BfArM directly. This decentralised approach has produced notable variation in processing times and local authority interpretation across Germany's 16 Länder. BfArM — the Bundesinstitut für Arzneimittel und Medizinprodukte, accessible at bfarm.de — provides federal oversight and has published detailed guidance notes, but licence decisions rest with local authorities.

A viable application requires a registered non-profit legal entity, a compliant cultivation premises with security infrastructure meeting BfArM standards, a documented youth protection concept, a cultivation and quality management plan, and evidence of financial sustainability. The BfArM guidance notes that cultivation operations must meet GACP (Good Agricultural and Collection Practice) standards, and all cannabis produced must be tested by an accredited laboratory.

For operators evaluating the Social Club model as a market entry strategy, the non-profit constraint is the binding limitation. Commercial returns cannot be extracted directly from the club structure. However, service contracts — for cultivation management, compliance consulting, security systems, laboratory testing and similar functions — provide a pathway for commercial operators to participate in the Social Club ecosystem without directly holding a non-profit licence.

Medical Cannabis: A Market Transformed

The reclassification of medical cannabis from the BtMG to the AMG is arguably the most commercially significant element of the CanG for international operators. Prior to April 2024, cannabis remained a Schedule I narcotic under German law even when prescribed medically — a legal inconsistency that created friction throughout the supply chain, complicated banking relationships and deterred some prescribers. Reclassification removed those anomalies.

Prescribing and Reimbursement

Under the post-CanG framework, any licensed physician in Germany may prescribe cannabis-based medicinal products (CBMPs) without restriction. The previous requirement for BfArM approval of individual prescriptions — which had acted as a significant bottleneck — was removed. Prescriptions are now issued on standard prescription forms (Kassenrezept for GKV patients) and dispensed through regular pharmacies.

GKV statutory health insurers — which cover approximately 90% of the German population — are required to reimburse CBMP prescriptions subject to a standard Wirtschaftlichkeitsprüfung (economic review) process. In practice, reimbursement approval rates have improved significantly since 2024, though individual insurers retain discretion on case-by-case decisions. The Bundesgesundheitsministerium (bundesgesundheitsministerium.de) publishes updated guidance on reimbursement criteria.

Market Size and Import Volumes

Germany's legal medical cannabis market is the largest in Europe and the fastest-growing in absolute terms. Conservative industry estimates place annual revenues at €400–600 million, with the trajectory pointing towards €1 billion by 2028 if prescription growth continues at current rates. The patient base is estimated to have passed 100,000 active GKV-reimbursed patients, with a significant additional cohort purchasing via private prescription.

Germany remains structurally dependent on imports. Domestic medical cannabis cultivation exists — BfArM conducted a tender process and awarded cultivation contracts — but domestic production capacity covers only a fraction of demand. Canada has historically been the dominant supplier, followed by the Netherlands (through Bedrocan), Portugal and Denmark. Portugal's growing cultivation sector and Denmark's established export-licensed companies have both increased market share.

For export-oriented operators, the German import market demands EU-GMP certification at the manufacturing level and GACP compliance at the cultivation level. These are non-negotiable requirements for accessing pharmacy channels. Third-party analytical testing to German Pharmacopoeia standards is also expected.

Pillar 2: The Commercial Retail Opportunity

Pillar 2 of the CanG — the regional commercial supply pilot programme — represents the commercially transformative element of German cannabis reform. Unlike Pillar 1's Social Club model, Pillar 2 will create a fully commercial supply chain: licensed cultivators, processors, distributors and retail outlets operating within a defined regional pilot framework.

As of early 2026, the federal government has published draft model legislation outlining the pilot structure. Participating Länder and municipalities will designate pilot zones within which licensed retailers may sell cannabis to adults. The key parameters under discussion include retail licensing requirements, municipal opt-in provisions, operating hours, product standards, packaging requirements and price floors designed to undercut the illicit market.

Berlin, Hamburg and Munich have publicly expressed interest in participating as early-mover pilot regions. Each has distinct regulatory cultures and urban demographics that will shape how pilots are implemented locally. Berlin, in particular, given its existing progressive stance and the high density of Social Clubs already operating in the city, is widely expected to move quickly once federal model legislation is finalised.

Strategic Positioning for Operators

Operators seeking to participate in Pillar 2 face a sequencing challenge: the legislative timeline remains uncertain, but supply chain positioning decisions — cultivation capacity, processing infrastructure, distribution partnerships, retail site identification — have long lead times. The risk of over-investing ahead of confirmed regulation must be weighed against the cost of being unpositioned when licensing opens.

The strategic moves available now include: establishing a German legal entity and corporate presence; building relationships with municipal authorities in target pilot regions; securing social club service contracts as a way to develop operational credibility and regulatory relationships; and monitoring federal legislative progress through BfArM and Bundesgesundheitsministerium channels.

Banking, Finance and Compliance Challenges

The normalisation of cannabis under German law has not yet translated into full normalisation of the banking relationship. Several major German financial institutions — including savings banks (Sparkassen) and some cooperative banks — continue to decline account opening requests from cannabis-related businesses, citing both international reputational risk and residual uncertainty around Pillar 2 commercial activity.

For Social Club operators and medical cannabis businesses that have been operational for 12–18 months, banking access has become more available through specialist providers and some challenger banks. However, operators should anticipate that establishing banking, insurance and payment processing relationships will require more due diligence engagement than in conventional sectors.

VAT and corporate tax treatment of cannabis businesses is settled under German law — cannabis operations are taxable commercial activities and must comply with standard Handelsgesetzbuch (HGB) accounting requirements. Cannabis is not currently subject to a specific excise duty, though the Pillar 2 legislation is expected to introduce one for retail products.

Quality Standards: GACP and EU-GMP

Any operator supplying cannabis into the German medical market must demonstrate compliance with two distinct but related quality frameworks. GACP (Good Agricultural and Collection Practice) is the cultivation-level standard, governing growing conditions, pest management, harvest procedures and post-harvest handling. EU-GMP (European Good Manufacturing Practice) is the manufacturing standard, governing extraction, formulation, packaging and quality control for finished medicinal products.

For cultivators in Portugal, Denmark or the Netherlands seeking to supply Germany, EU-GMP certification from the relevant national competent authority — Infarmed, DKMA or IGJ respectively — is required before product can enter German pharmaceutical distribution channels. BfArM audits and may inspect foreign cultivation and manufacturing facilities as part of import approval processes.

Intellectual property considerations are increasingly relevant for operators at scale. Cannabis genetics, proprietary extraction processes, and branded formulations are all protectable under German and EU IP law. Companies entering the German market in 2026 should ensure IP registration is complete before commercial launch, particularly for branded products that will require regulatory approval under the AMG framework.

Germany's Medical Cannabis Import Market